Pharmaceutical

Professor Robert Britton and Dr Ricardo Jorge Dinis-Oliveira bring drug development and pharmacology/toxicological expertise to Albert Labs' expanding R&D and Prescription Medicine activities

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50), or the "Company", a mental health research and drug development company have strengthened their Scientific Advisory Board, with the addition of Professor Robert Britton a Natural Product Chemist, and renowned toxicologist and pharmacologist, Dr. Dinis-Oliveira.

Albert Labs International Announces the Addition of Two Renowned Scientific Advisors to its Scientific Advisory Board (SAB) (CNW Group/Albert Labs International Corp.)

Professor Robert Britton, BSc , PhD, of Simon Fraser University , is a well-published natural product chemist with globally recognized expertise in natural product drug discovery, medicinal chemistry, and cancer therapeutics. With a particular focus on oncology, Prof. Britton creates new tools for late-stage modification of drug leads, new processes for improving the manufacture of drugs, and new strategies for synthesizing structurally complex natural products. Prior to his academic career, Prof. Britton was a Senior Scientist in the Process Research Group at Merck.

Dr. Ricardo Jorge Dinis-Oliveira , PhD, European PhD, DSc, is an expert Toxicologist and Pharmacologist. His scientific and academic focus is in the areas of toxicology and the pharmacology of psychoactive substances and medicines, focusing on their preclinical, and clinical development stages. He is a member of the editorial boards and ambassador to several international scientific journals. Dr. Dinis-Oliveira is extremely well-published, having authored more than 170 published articles in international indexed journals and peer-reviewed, and acted as author of some thirty-six book chapters, four books, four national and three international patents. In 2021 he was included on the world's top 2% of Scientists List, which ranks the most highly cited scientists globally. He has a passion for the pharmacology of psychoactive substances and has recently taken on the position of Editor-in-Chief of the newly formed journal, "Psychoactives", an international, peer-reviewed, journal on psychoactive substances.

Dr. Michael Raymont , CEO of Albert Labs , said, "We are delighted to welcome Professor Robert Britton and Dr. Dinis-Oliveira to our Scientific Advisory Board (SAB). Their exceptional expertise in natural product medicines and their depth of knowledge in toxicology and pharmacology, complement the expertise of our other SAB members. Improving drug discovery, and gaining a better understanding and depth of these compounds' pharmacodynamics and toxicology is critical to building value for Albert Labs shareholders as we advance toward our goal of delivering safe and effective drugs to revolutionize mental health treatment."

Professor Robert Britton added, "I'm excited to be working with Albert Labs . Fungi have been an important source of new medicines and are on the whole, pharmaceutically prolific and extremely promising. Albert Labs' scientific approach to natural product drug discovery and development is a promising step towards the creation of new medications for patients with urgent unmet needs and the development of a future pipeline of products for wider indications."

Dr. Dinis-Oliveira said, "My team and I will complete thorough toxicological & pharmacological testing to ensure that all of Albert Labs' clinical work, with KRN-101, is delivered safely and effectively. I am looking forward to assisting a company that will be safely administering psilocybin as a complement to psychotherapy and other pharmacological chemical treatments for people with urgent and unmet needs. This is especially the case for patients who are refractory to conventional treatments."

Business of Albert Labs Inc.

A clinical research and drug development enterprise, Albert Labs and its team of experts leverage advanced culture technology and natural extraction to accelerate the development of highly effective mental health medicines. Albert Labs look to develop solutions through an approved, fast track clinical pathway focusing on Real World Evidence (RWE). RWE studies are an increasingly recognized pathway heavily used in the successful development of Covid-19 vaccines. This accelerated development pathway will facilitate Albert Labs in delivering on its goal of receiving Market Authorization and creating highly successful, licensed medicines.

Through collaborations with research institutions, hospital centres and government agencies, Albert Labs uses existing clinical infrastructure to deliver and improve patient access to their treatment. Albert Labs' medicinal product, KRN-101, is being developed as a potential solution for cancer-related distress, a market of over 15 million people with some 1 million new sufferers each year. From this initial focus, Albert Labs will address broader mental health concerns, reported to affect over a billion people worldwide.

Albert Labs (CSE: ABRT) (FSE: VB50) recently completed a listing on the Canadian Securities Exchange (CSE) and filed a provisional patent for the scalable production of natural psilocybin medicine. You can find more details at albertlabs.com or watch a short "About Albert Labs" video here ( https://youtu.be/otQezIvmIXI ).

ON BEHALF OF THE BOARD OF DIRECTORS

Albert Labs International Corp.

Dr. Michael Raymont

Chief Executive Officer & Chairman

Website: https://albertlabs.com/

Cautionary Statement

This news release includes forward-looking statements that are subject to assumptions, risks, and uncertainties. Statements in this news release that are not purely historical are forward-looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, beliefs, or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate.

The Company cautions readers that all forward-looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward-looking statements. Readers are advised to rely on their evaluation of such risks and uncertainties and should not place undue reliance on forward-looking statements.

Any forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual events or results could or do differ from those projected in the forward-looking statements. The Company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events, or otherwise unless required by the applicable securities laws.

SOURCE Albert Labs International Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2022/26/c1546.html

News Provided by Canada Newswire via QuoteMedia

ABRT:CNX
Albert Labs

Albert Labs


Keep reading...Show less
Albert Labs

Albert Labs Appoints Principal Investigator for Real World Evidence Study for KRN-101

Albert Labs Appoints Dr Sara Tai as Principal Investigator for upcoming RWE Study on KRN-101

Albert Labs International Corp. ( Albert Labs (CSE: ABRT) (FSE: VB50), the "Company"), an R&D company developing mental health therapeutic medicines, is pleased to announce Dr. Sara Tai Senior Lecturer in Clinical Psychology from Manchester University, as Principal Investigator for its upcoming trial. The trial will evaluate the safety and efficacy of KRN-101, a psilocybin-based medicine, for the treatment of cancer-related distress, an indication thought to affect some 15 million patients in Europe and North America .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Albert Labs

Albert Labs Granted Health Canada Licence

Albert Labs has been issued a Health Canada License enabling the possession, production, and delivery of psilocybin and other psychoactive controlled substances

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50) (the "Company"), a research and drug development company using advanced culture technology to create pharmaceutical-quality medicines for mental health treatments, is pleased to report it has been granted a Health Canada License dated 05-05-2022 for its research and production facility in Burnaby, Canada . This approval permits the legal possession, production, assembly, sale, and delivery of psilocybin and other psychoactive controlled substances within the confines of the regulations governing controlled substances.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Albert Labs

Albert Labs' Pre-Clinical Analytical and Toxicological Research Supports Company's Forthcoming Studies

World-renowned scientists from the University of CESPU Health Sciences Department, Portugal are working in partnership with Albert Labs' expert team to conduct safety and toxicology studies, in preparation for KRN-101's use in Real World Evidence studies.

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50) (the "Company"), a research and drug development company using advanced culture technology to create pharmaceutical quality medicines, based on the mycelia of Psilocybe, today released further details of their ongoing preclinical studies. These are currently being conducted at the University of Health Sciences, CESPU, Portugal . The partnership established between Albert Labs and CESPU, provides Albert Labs with preclinical drug assessment capabilities, both in vivo and in vitro. The current work programme provides essential data on Albert Labs' mycelium-based pharmaceutical products in support of clinical trials due to start later this year. The clinical programme will investigate the potential to treat cancer-related distress, an indication thought to affect approximately 15 million patients worldwide.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Albert Labs Files US Provisional Patent Application and Proves Out Consistent and Rapidly Scalable Production of Psilocybe and Other Mycelia

Albert Labs Files US Provisional Patent Application and Proves Out Consistent and Rapidly Scalable Production of Psilocybe and Other Mycelia

Albert Labs' Files U.S. Provisional Patent Application for a Cultivation Process for the Production of Psilocybe mycelia as well as other Fungi Species

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50) (the "Company"), a research and drug development company using advanced culture technology to create pharmaceutical-quality medicines, based on mycelia of Psilocybe and other fungi, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a proprietary process. Albert Labs' culturing process can significantly increase the production volumes of psilocybin medicine. The Company sees the demand for naturally produced psilocybin continuing to increase as the unmet needs for mental health treatment hit crisis levels worldwide.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

  • Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a 9.1 and 10.9-fold increase against Omicron
  • Geometric mean ratios for Omicron neutralizing antibody response consistent with regulatory requirement of superiority
  • Preliminary laboratory studies demonstrate both Omicron-adapted candidates neutralize Omicron BA.4 and BA.5 though to a lesser extent than they do for BA.1
  • Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
  • Data to be discussed with regulators with goal of rapidly introducing adapted booster to address current and future variants

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent, a combination of the Pfizer-BioNTech COVID-19 Vaccine and a vaccine candidate targeting the spike protein of the Omicron BA.1 variant of concern. Data from the Phase 2/3 trial found that a booster dose of both Omicron-adapted vaccine candidates elicited a substantially higher immune response against Omicron BA.1 as compared to the companies' current COVID-19 vaccine. The robust immune response was seen across two investigational dose levels, 30 µg and 60 µg.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220625005002/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Thursday, July 28, 2022. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2022 Performance Report, to be issued that morning.

To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors . Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

European Commission Approves KEYTRUDA® as Adjuvant Treatment for Adult and Adolescent Patients With Stage IIB or IIC Melanoma Following Complete Resection

Approval based on recurrence-free survival and distant metastasis-free survival benefit demonstrated by KEYTRUDA in the Phase 3 KEYNOTE-716 trial

KEYTRUDA is the first anti-PD-1 immunotherapy approved in the EU for patients 12 years and older as adjuvant treatment across stage IIB, IIC and III melanoma following complete resection and for the treatment of advanced (unresectable or metastatic) melanoma

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

European Commission Approves KEYTRUDA® as Adjuvant Treatment for Adult and Adolescent Patients With Stage IIB or IIC Melanoma Following Complete Resection

Approval based on recurrence-free survival and distant metastasis-free survival benefit demonstrated by KEYTRUDA in the Phase 3 KEYNOTE-716 trial

KEYTRUDA is the first anti-PD-1 immunotherapy approved in the EU for patients 12 years and older as adjuvant treatment across stage IIB, IIC and III melanoma following complete resection and for the treatment of advanced (unresectable or metastatic) melanoma

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

European Commission Approves KEYTRUDA® as Adjuvant Treatment for Adult and Adolescent Patients With Stage IIB or IIC Melanoma Following Complete Resection

Approval based on recurrence-free survival and distant metastasis-free survival benefit demonstrated by KEYTRUDA in the Phase 3 KEYNOTE-716 trial

KEYTRUDA is the first anti-PD-1 immunotherapy approved in the EU for patients 12 years and older as adjuvant treatment across stage IIB, IIC and III melanoma following complete resection and for the treatment of advanced (unresectable or metastatic) melanoma

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

European Commission Approves KEYTRUDA® as Adjuvant Treatment for Adult and Adolescent Patients With Stage IIB or IIC Melanoma Following Complete Resection

Approval based on recurrence-free survival and distant metastasis-free survival benefit demonstrated by KEYTRUDA in the Phase 3 KEYNOTE-716 trial

KEYTRUDA is the first anti-PD-1 immunotherapy approved in the EU for patients 12 years and older as adjuvant treatment across stage IIB, IIC and III melanoma following complete resection and for the treatment of advanced (unresectable or metastatic) melanoma

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×